139264-55-4

Basic information

• Product Name: (S)-4-(4-Nitrobenzyl)-2-oxazolidinone
• Synonyms: (S)-4-(4-Nitrobenzyl)-2(1 H)-oxazolidinone;(S)-4-[(4-Nitrophenyl)methyl]-2-oxazolidinone
• CAS NO: 139264-55-4
• Molecular Formula: C₁₀H₁₀N₂O₄
• Molecular Weight: 222.1974
• Mol File: 139264-55-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 509.509 °C at 760 mmHg
• Flash Point: 261.942 °C
• Appearance: /
• Density: 1.367
• Storage Temp.: 2-8°C
• PKA: 12.24±0.40(Predicted)
• CAS DataBase Reference: (S)-4-(4-Nitrobenzyl)-2-oxazolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(4-Nitrobenzyl)-2-oxazolidinone(139264-55-4)
• EPA Substance Registry System: (S)-4-(4-Nitrobenzyl)-2-oxazolidinone(139264-55-4)

Safety Data

• Hazardous Substances Data: 139264-55-4(Hazardous Substances Data)

Usage

Uses

(4S)-4-[(4-Nitrophenyl)methyl]-2-oxazolidinone is an impurity in the synthesis of 3-Des[2-(Dimethylamino)ethyl] Zolmitriptan-d6 3-Acetic Acid (D288969) which is the isotope labelled 3-Des[2-(Dimethylamino)ethyl] Zolmitriptan 3-Acetic Acid (D288965). 3-Des[2-(Dimethylamino)ethyl] Zolmitriptan 3-Acetic Acid is the indole acetic acid metabolite of Zolmitriptan (Z639000) formed by human hepatocytes.

Upstream product

• 75-44-5 phosgene 
• 89288-22-2 (S)-(-)-2-amino-3-(4-nitrophenyl)propan-1-ol 
• 17193-40-7 (S)-4-nitrophenylalanine methyl ester hydrochloride 
• 63-91-2 L-phenylalanine 
• 105-58-8 Diethyl carbonate 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 949-99-5 4-nitro-3-phenyl-L-alanine 
• 32315-10-9 bis(trichloromethyl) carbonate 

Downstream Products

• 152305-23-2 (S)-4-(4-aminobenzyl)-1,3-oxazolidin-2-one 
• 1020737-23-8 (4S)-4-(4-nitrobenzyl)-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one 
• 1610608-12-2 (S)-3-((1S,2R)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 1610608-07-5 (S)-3-((1R,2S)-1,2-diethyl-2-vinylcyclopropanecarbonyl)-4-(4-nitrobenzyl)oxazolidin-2-one 
• 139264-15-6 (S)-2-<5-<(2-oxo-1,3-oxazolidin-4-yl)methyl>-1H-indol-3-yl>ethylamine 
• 139264-57-6 (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride 
• 191864-24-1 ethyl 3-(2-dimethylaminoethyl)-5-[(4S)-2-oxooxazolidin-4-ylmethyl]-1H-indole-2-carboxylate 

Relevant articles and documents

Asymmetric synthesis of 3,3,5,5-tetrasubstituted 1,2-dioxolanes: Total synthesis of epiplakinic acid F

The first enantioselective total synthesis of epiplakinic acid F (1) was achieved through a pivotal step involving a radical-mediated asymmetric peroxidation of vinylcyclopropanes with molecular oxygen to construct highly substituted 1,2-dioxolanes. Subsequent conversions of the chiral 1,2-dioxolanes led to total synthesis of epiplakinic acid F (1) and the confirmation of its absolute configuration. The enantiomer of epiplakinic acid F methyl ester (2) was also prepared. This journal is the Partner Organisations 2014.

Design, synthesis, and evaluation of 4-(4′-aminobenzyl)-2-oxazolidinones as novel inhibitors of the cytochrome P-450 enzyme aromatase

The synthesis of a series of N-alkylated 4-(4′aminobenzyl)-2-oxazolidinones is described using a synthetically useful scheme which avoids the use of phosgene - since the derivatization is undertaken with the oxazolidin-2-one ring intact. The compounds were tested for human placental aromatase (AR) inhibition in vitro, using [1β, 2β-3H]androstenedione as substrate for the AR enzyme. The compounds were found, in general, to be more potent than the standard compound, amino-glutethimide (AG), and as such proved to be good lead compounds in the search for more specific AR inhibitors.

Indolyl tetrahydropyridines for treating migraine

STR1 The present invention is concerned with compounds of formula (I), wherein n is an integer of from 0 to 3: W is a group of formula (i), (ii), or (iii), wherein R is hydrogen or C1-4 alkyl, X is --O--, --S--, --NH--, or --CH2 --, Y is oxygen or sulphur and the chiral center (*) in formula (i) or (ii) is in its (S) or (R) form or is a mixture thereof in any proportions: and Z is a group of formula (iv), (v), or (vi), wherein R1 and R2 are independently selected from hydrogen and C1-4 alkyl and R3 is hydrogen or C1-4 alkyl; and their salts, solvates and physiologically functional derivatives, with processes for their preparation, with medicaments containing them and with their use as therapeutic agents, particularly in the prophylaxis and treatment of migraine.